Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Iron isomaltoside 1000 (Monoferric -- pharmacosmos A/S) indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy, the diagnosis must be based on laboratory tests

The CADTH Canadian Drug Expert Committee (CDEC) recommends that iron isomaltoside 1000 (Monoferric) be reimbursed for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance of or unresponsiveness to oral iron therapy only if the following conditions are met: Conditions...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH March 27, 2020, 2020
Edition:Version: final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Disaccharides / Therapeutic Use
Canada
Anemia, Iron-deficiency / Drug Therapy
Ferric Compounds / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that iron isomaltoside 1000 (Monoferric) be reimbursed for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance of or unresponsiveness to oral iron therapy only if the following conditions are met: Conditions for Reimbursement Prescribing condition 1. The drug must be administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided. Pricing condition 1. Reduced price
Physical Description:1 PDF file (unpaged)

Similar Items